Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial): An Umbrella-Basket Platform Trial to Evaluate the Efficacy of Targeted Therapies in Rare Adult, Paediatric and Teenage/Young Adult (TYA) Cancers With Actionable Genomic Alterations, Including Common Cancers With Rare Actionable Alterations. Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and TYA Patients With BRAF V600 Mutation-Positive Cancers.

NCT07440290 is registered in ClinicalTrials.gov with Cancer Research UK as lead sponsor.

NCT NCT07440290
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07440290 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial): An Umbrella-Basket Platform Trial to Evaluate the Efficacy of Targeted Therapies in Rare Adult, Paediatric and Teenage/Young Adult (TYA) Cancers With Actionable Genomic Alterations, Including Common Cancers With Rare Actionable Alterations. Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and TYA Patients With BRAF V600 Mutation-Positive Cancers.
Lead sponsor
Cancer Research UK
Phase
Phase 2/3
Overall status
Recruiting
Start date
April 1, 2026
Completion date
October 31, 2029
Enrollment
30 (estimated)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, carcinoma, non-small cell-lung, colorectal neoplasms, erdheim-chester disease, gastrointestinal cancer, glioma, haematological malignancy, langerhans cell histiocytosis (lch), laryngeal neoplasms, lymphoproliferative disorders, malignant neoplasm, multiple myeloma, neoplasms by histologic type, neoplasms by site, non-melanoma skin cancer (nmsc), ovarian neoplasms, pancreatic diseases, solid tumour, thyroid carcinoma, anaplastic, thyroid carcinoma, papillary